Prostate cancer: Molecular approaches for detection and prognosis, and angiogenic therapeutic targets

References 

1. Srigley JR , Amin M , Boccon-Gibod L , et al.   Prognostic and predictive factors in prostate cancer (Historical perspectives and recent international consensus initiatives) . Scand J Urol Nephrol Suppl . 2005;216:8–19
2. Calvo A , Gonzalez-Moreno O , Yoon CY , et al.   Prostate cancer and the genomic revolution (Advances using microarray analyses) . Mutat Res . 2005;576:66–79
   • MEDLINE
   • CrossRef
3. Manley S , Mucci NR , DeMarzo AM , et al.   Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome (The prostate specialized program of research excellence model) . Am J Pathol . 2001;159:837–843
   • Abstract
   • Full Text
   • Full-Text PDF (1060 KB)
   • CrossRef
4. Veenstra TD , Conrads TP . Serum protein fingerprinting . Curr Opin Mol Ther . 2003;5:584–593
   • MEDLINE
5. Schmitt M , Harbeck N , Daidone MG , et al.   Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients . Tasks of the receptor and biomarker group of the European Organization for Research and Treatment of Cancer Int J Oncol . 2004;25:1397–1406
6. Makridakis NM , Reichardt JK . Molecular epidemiology of androgen-metabolic loci in prostate cancer (Predisposition and progression) . J Urol . 2004;171:S25–S28
   • Abstract
   • Full Text
   • Full-Text PDF (75 KB)
   • CrossRef
7. Armstrong AJ , Carducci MA . Advanced prostate cancer (The future) . Can J Urol . 2005;12(Suppl 2):42–47
8. Figg WD , Franks ME , Venzon D , et al.   Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer . World J Urol . 2004;22:425–430
   • MEDLINE
   • CrossRef
9. Wang X , Yu J , Sreekumar A , et al.   Autoantibody signatures in prostate cancer . N Engl J Med . 2005;353:1224–1235
   • CrossRef